article · Immuno
Inflammatory bowel disease is a chronic and complex inflammatory condition affecting the digestive tract, primarily categorised into ulcerative colitis and Crohn's disease. While the precise causes of the disease remain unclear, imbalance or dysbiosis within the gut microbiota is considered an important driver of disease progression. The gut microbiome functions effectively as a metabolic organ, supporting general health through diverse biological processes. Changes in the composition of these microbial communities can trigger pathological states. Detailed attention is given to the metabolic interactions between the host and the microbiome, including how shifts in bacteria, viruses, and fungi correlate with inflammatory bowel disease progression. Consequently, therapies aimed directly at modifying or restoring the gut microbiome represent a promising and novel pathway for managing and treating these chronic gut disorders.
Chronic gut diseases affect millions of people, yet their root causes remain difficult to resolve. Understanding how the gut microbiome and its metabolic processes influence health provides new opportunities to tackle debilitating conditions like Crohn's disease and ulcerative colitis. Moving beyond conventional treatments towards targeted microbiome management could offer more effective strategies for long-term patient care.
This work highlights microbiome-based therapies as an intervention strategy for managing ulcerative colitis and Crohn's disease. Potential applications target healthcare providers and biopharmaceutical developers creating microbiome-modulating treatments. Because the source material is a review examining biological mechanisms and therapy concepts, the insights remain at an early, exploratory stage rather than offering an immediate commercial product.
AI-generated from the published abstract. Always read the original work before citing.
Inflammatory bowel disease (IBD) is a chronic complicated inflammatory gut pathological disorder and is categorized into ulcerative colitis (UC) and Crohn’s disease (CD). Although the cause of IBD is unclear, dysbiosis of the gut microbiota is thought to be a key factor in the disease’s progression. The gut microbiome serves as a metabolic organ and promotes wellness by carrying out several biological activities. Any modification in the makeup of the gut microbiome leads to several pathological conditions, including IBD. In this review, we emphasize the key metabolic processes that control host–microbiome interaction and its impact on host health. We also discuss the association between microbiome dysbiosis (bacteriome, virome, and mycobiome) and the progression of IBD. Finally, we will highlight microbiome-based therapy as a novel and promising strategy to treat and manage IBD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/immuno4040026
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
